Figure 2.
Disease-free survival by ZNF331 promoter methylation status. (a) DFS OS is based on ZNF331 promoter methylation status in the total analysis population (N = 385). There was no significant difference in DFS in patients with methylated versus unmethylated ZNF331 colon cancers. (b) Evaluation of ZNF331 promoter methylation status as a prognostic marker of DFS.